Cough dynamics in adults receiving tuberculosis treatment.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
12
2019
accepted:
17
03
2020
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
20
8
2020
Statut:
epublish
Résumé
Cough is a characteristic symptom of tuberculosis, is the main cause of transmission, and is used to assess treatment response. We aimed to identify the best measure of cough severity and characterize changes during initial tuberculosis therapy. We conducted a prospective cohort of recently diagnosed ambulatory adult patients with pulmonary tuberculosis in two tertiary hospitals in Lima, Peru. Pre-treatment and five times during the first two months of treatment, a vibrometer was used to capture 4-hour recordings of involuntary cough. A total of 358 recordings from 69 participants were analyzed using a computer algorithm. Total time spent coughing (seconds per hour) was a better predictor of microbiologic indicators of disease severity and treatment response than the frequency of cough episodes or cough power. Patients with prior tuberculosis tended to cough more than patients without prior tuberculosis, and patients with tuberculosis and diabetes coughed more than patients without diabetes co-morbidity. Cough characteristics were similar regardless of HIV co-infection and for drug-susceptible versus drug-resistant tuberculosis. Tuberculosis treatment response may be meaningfully assessed by objectively monitoring the time spent coughing. This measure demonstrated that cough was increased in patients with TB recurrence or co-morbid diabetes, but not because of drug resistance or HIV co-infection.
Identifiants
pubmed: 32511248
doi: 10.1371/journal.pone.0231167
pii: PONE-D-19-31712
pmc: PMC7279573
doi:
Substances chimiques
Antitubercular Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0231167Subventions
Organisme : FIC NIH HHS
ID : D43 TW009349
Pays : United States
Organisme : FIC NIH HHS
ID : R25 TW009340
Pays : United States
Organisme : Wellcome Trust
ID : 057434/Z/99/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 070005/Z/02/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 078340/Z/05/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 105788/Z/14/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 201251/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K007467/1
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Breath Res. 2016 Oct 18;10(4):045001
pubmed: 27753432
Presse Med. 2017 Mar;46(2 Pt 2):e23-e39
pubmed: 28256380
Cough. 2010 May 27;6:3
pubmed: 20504377
Front Public Health. 2014 Dec 22;2:281
pubmed: 25566523
BMC Health Serv Res. 2013 Jul 31;13:290
pubmed: 23899353
J Infect Dis. 2015 May 1;211(9):1367-72
pubmed: 25387581
Clin Infect Dis. 2017 May 1;64(9):1174-1181
pubmed: 28329268
Lung. 2008;186 Suppl 1:S55-8
pubmed: 17939003
Conf Proc IEEE Eng Med Biol Soc. 2011;2011:6017-20
pubmed: 22255711
Am J Respir Crit Care Med. 2013 May 1;187(9):943-9
pubmed: 23471467
Eur Respir J. 2013 Jan;41(1):241-3
pubmed: 23277523
BMJ Open Respir Res. 2017 May 12;4(1):e000178
pubmed: 28725446
Eval Program Plann. 2015 Apr;49:10-8
pubmed: 25462937
J Clin Microbiol. 2004 Oct;42(10):4432-7
pubmed: 15472289
BMJ Open. 2016 Apr 22;6(4):e010365
pubmed: 27105713
PLoS One. 2012;7(10):e46229
pubmed: 23071550
N Engl J Med. 2006 Oct 12;355(15):1539-50
pubmed: 17035648
Int J Tuberc Lung Dis. 2018 Aug 1;22(8):863-870
pubmed: 29991394
PLoS One. 2016 Jan 11;11(1):e0146876
pubmed: 26752596
Lancet Respir Med. 2018 Apr;6(4):244-246
pubmed: 29595504
Chest. 2018 Jun;153(6):1358-1367
pubmed: 29559307
J Clin Microbiol. 2000 Mar;38(3):1203-8
pubmed: 10699023